Extensive work has been done over the past decade to determine the best drug regimen for the treatment of nocturnal asthma. Much of the work has been directed at the evaluation of theophylline preparations and sympathomimetic agents. With a better understanding of the mechanisms causing nocturnal asthma, future therapeutic advances will be targeted at the underlying pathophysiological causes of the disorder. This article wilt review current treatment modalities, including those shown to have some effect as welt as those that have no benefit.
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.